PL356721A1 - Zastosowanie mirtazapiny do leczenia zaburzeń snu - Google Patents

Zastosowanie mirtazapiny do leczenia zaburzeń snu

Info

Publication number
PL356721A1
PL356721A1 PL01356721A PL35672101A PL356721A1 PL 356721 A1 PL356721 A1 PL 356721A1 PL 01356721 A PL01356721 A PL 01356721A PL 35672101 A PL35672101 A PL 35672101A PL 356721 A1 PL356721 A1 PL 356721A1
Authority
PL
Poland
Prior art keywords
mirtazapine
treatment
sleep disorders
sleep
disorders
Prior art date
Application number
PL01356721A
Other languages
English (en)
Other versions
PL206073B1 (pl
Inventor
Stephanus Franciscus Ruigt Gerardus
Der Berg Frans Van
Original Assignee
Akzo Nobel N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel N.V. filed Critical Akzo Nobel N.V.
Publication of PL356721A1 publication Critical patent/PL356721A1/pl
Publication of PL206073B1 publication Critical patent/PL206073B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL356721A 2000-02-11 2001-02-06 Zastosowanie mirtazapiny do wytwarzania leku PL206073B1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00200499 2000-02-11
PCT/EP2001/001221 WO2001058453A1 (en) 2000-02-11 2001-02-06 The use of mirtazapine for the treatment of sleep disorders

Publications (2)

Publication Number Publication Date
PL356721A1 true PL356721A1 (pl) 2004-06-28
PL206073B1 PL206073B1 (pl) 2010-06-30

Family

ID=8171013

Family Applications (1)

Application Number Title Priority Date Filing Date
PL356721A PL206073B1 (pl) 2000-02-11 2001-02-06 Zastosowanie mirtazapiny do wytwarzania leku

Country Status (25)

Country Link
US (1) US6933293B2 (pl)
EP (4) EP1658850A1 (pl)
JP (1) JP5039994B2 (pl)
KR (1) KR20020069371A (pl)
CN (2) CN101229170A (pl)
AR (1) AR027394A1 (pl)
AT (1) ATE317261T1 (pl)
AU (1) AU780439B2 (pl)
BR (1) BR0108261A (pl)
CA (1) CA2396209C (pl)
CO (1) CO5271706A1 (pl)
CZ (1) CZ302368B6 (pl)
DE (1) DE60117122T2 (pl)
DK (1) DK1257278T3 (pl)
ES (1) ES2258071T3 (pl)
HK (1) HK1049122B (pl)
HU (1) HUP0204391A3 (pl)
IL (2) IL150290A0 (pl)
NO (1) NO328007B1 (pl)
PE (1) PE20011080A1 (pl)
PL (1) PL206073B1 (pl)
RU (1) RU2270680C2 (pl)
SK (1) SK287396B6 (pl)
WO (1) WO2001058453A1 (pl)
ZA (1) ZA200205238B (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040152055A1 (en) * 2003-01-30 2004-08-05 Gliessner Michael J.G. Video based language learning system
UA83666C2 (ru) 2003-07-10 2008-08-11 Н.В. Органон Способ получения энантиомерно чистого миртазапина
EP1689371A2 (en) * 2003-11-25 2006-08-16 Aurobindo Pharma Limited Pharmaceutical compositions of mirtazapine
GB0417558D0 (en) * 2004-08-06 2004-09-08 Merck Sharp & Dohme Novel combination therapy
EP1806133A1 (en) * 2004-10-14 2007-07-11 Daikin Industries, Ltd. Method for modifying the ambience, and spray liquid and sprayer used in the method
JP2006137748A (ja) * 2004-10-14 2006-06-01 Daikin Ind Ltd 雰囲気改変方法、並びに、それに用いられる噴霧剤及び噴霧装置
JP2007284363A (ja) * 2006-04-13 2007-11-01 Daikin Ind Ltd 噴霧剤
CN101679431B (zh) 2007-04-11 2013-08-14 Msd欧斯股份有限公司 制备四环苯并氮杂卓的对映异构体的方法
WO2016138357A1 (en) 2015-02-27 2016-09-01 Kindred Biosciences, Inc. Stimulation of appetite, management of weight loss, and treatment of anorexia in dogs and cats
CN111053735A (zh) * 2020-02-25 2020-04-24 上海阶平医院管理有限公司 一种治疗失眠的冷敷凝胶

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL189199C (nl) 1975-04-05 1993-02-01 Akzo Nv Werkwijze ter bereiding van farmaceutische preparaten met werking op het centraal zenuwstelsel op basis van benz(aryl)azepinederivaten, de verkregen gevormde farmaceutische preparaten, alsmede werkwijze ter bereiding van de toe te passen benz(aryl)azepinederivaten.
DE69307908T2 (de) * 1992-10-07 1997-07-10 Akzo Nobel Nv Verfahren zur trennung von enantiomeren aus einer racemischen mischung
EP0813873B1 (en) 1996-06-19 2002-02-13 Akzo Nobel N.V. Pharmaceutical composition comprising mirtazapine and one or more selective serotonin reuptake inhibitors
IL121076A (en) * 1996-06-19 2000-10-31 Akzo Nobel Nv Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors
JP2001522891A (ja) * 1997-11-14 2001-11-20 アクゾ・ノベル・エヌ・ベー 睡眠時無呼吸を治療するためのミルタザピンの使用

Also Published As

Publication number Publication date
ES2258071T3 (es) 2006-08-16
PE20011080A1 (es) 2001-10-18
JP2003522147A (ja) 2003-07-22
SK287396B6 (sk) 2010-08-09
DE60117122D1 (de) 2006-04-20
US6933293B2 (en) 2005-08-23
CZ20022330A3 (cs) 2002-11-13
WO2001058453A1 (en) 2001-08-16
HK1049122B (en) 2006-04-21
IL150290A (en) 2010-12-30
US20030022888A1 (en) 2003-01-30
HUP0204391A2 (en) 2003-05-28
CA2396209A1 (en) 2001-08-16
AU780439B2 (en) 2005-03-24
CO5271706A1 (es) 2003-04-30
RU2270680C2 (ru) 2006-02-27
PL206073B1 (pl) 2010-06-30
EP1658850A1 (en) 2006-05-24
DK1257278T3 (da) 2006-06-12
NO20023803D0 (no) 2002-08-09
DE60117122T2 (de) 2006-07-27
ATE317261T1 (de) 2006-02-15
EP1257278B1 (en) 2006-02-08
ZA200205238B (en) 2003-09-29
AR027394A1 (es) 2003-03-26
RU2002124141A (ru) 2004-03-10
HK1049122A1 (en) 2003-05-02
IL150290A0 (en) 2002-12-01
EP1257278A1 (en) 2002-11-20
NO328007B1 (no) 2009-11-09
CZ302368B6 (cs) 2011-04-13
SK11442002A3 (sk) 2003-02-04
NO20023803L (no) 2002-10-09
KR20020069371A (ko) 2002-08-30
EP1656937A1 (en) 2006-05-17
BR0108261A (pt) 2003-03-05
AU3024701A (en) 2001-08-20
EP2283840A1 (en) 2011-02-16
CN101229170A (zh) 2008-07-30
HUP0204391A3 (en) 2005-03-29
JP5039994B2 (ja) 2012-10-03
CA2396209C (en) 2009-09-01
CN1395487A (zh) 2003-02-05

Similar Documents

Publication Publication Date Title
GB0007193D0 (en) Treatment of movrmrnt disorders
IL160389A0 (en) Use of flibanserin for the treatment of sexual disorders
PT2266594E (pt) Vegf para utilização no tratamento de distúrbios do sistema nervoso central
IL196301A0 (en) Medicament for the treatment of hapatitis c
IL153425A0 (en) Sulfonyl-pyrrolidine derivatives useful for the treatment of neurological disorders
HUP0203529A3 (en) Treating sleep disorders using desloratadine
IL151890A0 (en) Hydroxyphenyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain
IL155589A0 (en) Novel amidoalkyl-piperidine and amidoalkyl-piperazine derivatives useful for the treatment of nervous system disorders
IL157145A0 (en) Use of dc23 antagonists for the treatment of neoplastic disorders
IL155433A0 (en) Treatment of t cell disorders
GB0004531D0 (en) The treatment of respiratory diseases
IL150289A0 (en) Drug combination for the treatment of depression and related disorders comprising mirtazapine
IL151765A0 (en) Hydroxyphenyl-piperazinyl-methyl-benzamide derivatives for the treatment of pain
IL150290A0 (en) The use of mirtazapine for the treatment of sleep disorders
IL151891A0 (en) Quinolinyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain
AU2001251306A1 (en) Treatment of sleep disorders with hypocretin-1
GB0128674D0 (en) Treatment of sleep disorders and the like
HRP20030384A2 (en) Treatment of anxiety disorders
CZ20011872A3 (cs) Isonipekotamidy pro léčbu onemocnění zprostředkovaných integriny
PT1698338E (pt) S-metil-di-hidro-ziprasidona para o tratamento de distúrbios psiquiátricos
AU4838301A (en) Treatment of disorders relating to the serotonergic system
GB0010496D0 (en) Treatment of conditions of the central nervous system
HRP20041159A2 (en) Combination for the treatment of airway disorders
IL153788A0 (en) Treatment of eating disorders using carboxyalkylethers
HK1063438A (en) Treatment of anxiety disorders

Legal Events

Date Code Title Description
LAPS Decisions on the lapse of the protection rights

Effective date: 20120206